Analysts at Oppenheimer downgraded Taser International Inc. (TASR) from ‘Outperform‘ to ‘Perform‘ in a research report issued to clients on Thursday.
On valuation measures, Taser Int’l Inc. stock it’s trading at a forward P/E multiple of 58.64x, and at a multiple of 88.81x this year’s estimated earnings. The t-12-month revenue at Taser is $173.10 million. TASR ‘s ROE for the same period is 17.99%.
Shares of the $1.75 billion market cap company are up 160.68% year-over-year and 29.95% year-to-date.
Taser International Inc., currently with a median Wall Street price target of $31.00 and a high target of $35.00, dropped $1.55 to $32.86 in recent trading.
The chart below shows where the equity has traded over the past 52-weeks.
3D Systems Corporation (DDD) was reiterated as ‘Buy’ but with a $28 from $32 price target on Thursday by Needham.
DDD shares recently lost $0.91 to $21.99. The stock is down more than 54% year-over-year and has lost roughly 31% year-to-date. In the past 52 weeks, shares of Charlotte, North Carolina-based company have traded between a low of $21.95 and a high of $69.56.
3D Systems Corp. closed Wednesday at $22.90. The name has a total market cap of $2.46 billion.
Sequenom Inc. (SQNM) was downgraded from ‘Outperform‘ to ‘Neutral‘ at Wedbush.
Shares have traded today between $3.92 and $4.50 with the price of the stock fluctuating between $2.61 to $4.80 over the last 52 weeks.
Sequenom Inc. shares are currently changing hands at 440x this year’s forecasted earnings, compared to the industry’s (16.47)x earnings multiple. Ticker has a t-12 price/sales ratio of 3.48. EPS for the same period registers at $0.01.
Shares of SQNM have lost $0.51 to $3.96 in mid-day trading on Thursday, giving it a market cap of roughly $468 million. The stock traded as high as $4.80 in May 5, 2015.
JMP Securities reported on Thursday that they have lowered their rating for OraSure Technologies, Inc. (OSUR). The firm has downgraded OSUR from ‘Market Outperform‘ to ‘Market Perform‘.
OraSure recently traded at $5.38, a loss of $0.78 over Wednesday’s closing price. The name has a current market cap of $307.26 million.
Sucampo Pharmaceuticals, Inc. (SCMP) was downgraded by WallachBeth from a ‘Buy‘ rating to a ‘Hold‘ rating in a research report issued to clients on Thursday. They currently have a $19 price objective on the stock, 1 point up from their previous price target of $18.
SCMP closed at $18.06 on Wednesday and is currently trading down $3.00.
In the past 52 weeks, shares of Bethesda, Maryland-based company have traded between a low of $5.80 and a high of $22.00 and are now trading at $15.06. Shares are up 165.98% year-over-year and 26.47% year-to-date.